Tested immune-cell therapy for drug-resistant tuberculosis
Part of Infections clinical trials.
This trial studies an immune-based treatment made from certain T cells (Vγ2Vδ2 T lymphocytes) for multi-drug–resistant tuberculosis (MDR-TB). It may help people whose current drug regimen is not working well or who have limited effective options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have drug-resistant TB that does not respond to at least isoniazid and rifampicin
- Your current treatment is working poorly, or you have no response, or fewer than 4 TB medicines are still expected to work
- You do not have major problems that weaken the immune system from other medical conditions
- You should not test as having a poor immune response to ZOL and IL-2 stimulation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests whether an experimental vaccine (ID93 + GLA-SE) can improve outcomes in people being treated for drug-sensitive tuberculosis. It is for those newly diagnosed or who have been on standard TB treatment for a few months.
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
This trial tests a new treatment using special immune cells called Vγ9Vδ2 T cells, given directly into the brain fluid. It is for people with a very aggressive grade 4 brain tumor (malignant glioma) that has not gotten better with standard treatments.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.
Hear when a new MDR-TB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.